In a model with human triple negative breast cancer-derived BT-549 cells, shRNA-conferred knockdown of GRP78 was demonstrated to sensitize the GRP78-depleted cancer cells to doxorubicin and cisplatin [140]. This evidence concerns the gene HSPA5 and triple-negative breast carcinoma.